Dr. Samer Al Hadidi Discusses CAR-T MM Data Presented at the FDA ODAC Meeting

In this episode of “Blood Cancer Talks,” Samer Al Hadidi, MD, of the University of Arkansas Myeloma Center, joins hosts Raj Chakraborty, MD; Ashwin Kishtagari, MD; and Edward Cliff, MD, to discuss overall survival data from the CARTITUDE-4 and KarMMa-3 trials presented at the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) meeting on March 15, 2024.

The KarMMa-3 trial compared idecabtagene vicleucel (ide-cel) with standard regimens in relapsed or refractory multiple myeloma (MM), while the CARTITUDE-4 trial compared ciltacabtagene autoleucel (cilta-cel) with standard of care in patients with MM who are refractory to lenalidomide.

This podcast originally appeared on Blood Cancer Talks.